Maximizing the therapeutic benefit of vinblastine treatment of BRCA1-associated mammary tumors would be facilitated by the ability to distinguish potential responders by analyzing the tumor at baseline (i.e., before initiation of treatment). The gene discussed is BRCA1; the disease is breast cancer.